EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer

Rubi Roy, Tasnim Ria, Debapriya RoyMahaPatra, Ugir Hossain Sk iD

ACS Omega · 16.05.2023 · 8 (19) · 16532-16544

DOI: 10.1021/acsomega.3c00222 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Omega, online erschienen am 01.05.2023. Verfasst von Rubi Roy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Translational Research, Chittaranjan National Cancer Institute, 37 S.P. Mukherjee Road, Kolkata, West Bengal 700026, India. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Council of Scientific and Industrial Research, India.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to the multimodal character of cancer, inhibition of two targets simultaneously by a single molecule is a beneficial and effective approach against cancer. Histone deacetylase (HDAC) was widely investigated as a novel category of anticancer drug targets due to its crucial role in various biological processes like cell-proliferation, metastasis, and apoptosis. Numerous HDAC inhibitors such as vorinostat and panobinostat are clinically approved but have limited usage due to their low efficacy, nonselectivity, drug resistance, and toxicity. Therefore, HDACs with a dual targeting ability have attracted great attention. The strategy of combining a HDAC inhibitor with other antitumor agents has been proved advantageous for combating the nonselectivity and drug resistivity problems associated with single-target drugs. Henceforth, we have highlighted dual-targeting inhibitors to target HDAC along with topoisomerase, receptor tyrosine kinase inhibitors, and the zeste homolog 2 enzyme. Our Review mainly focuses on the impact of the substituent effect along with the linker variation of well-known HDAC-inhibitor-conjugated anticancer drugs.

Autor:innen und Institutionen

  • Department of Clinical and Translational Research, Chittaranjan National Cancer Institute, 37 S.P. Mukherjee Road, Kolkata, West Bengal 700026, India.

ORCID-Profile: Ugir Hossain Sk

Förderung

  • Council of Scientific and Industrial Research, India

Zitieren

APA

Roy, R., Ria, T., RoyMahaPatra, D., & Sk, U. H. (2023). Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer. ACS Omega, 8(19), 16532-16544. https://doi.org/10.1021/acsomega.3c00222

Vancouver

Roy R, Ria T, RoyMahaPatra D, Sk UH. Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer. ACS Omega. 2023;8(19):16532-16544. doi:10.1021/acsomega.3c00222

BibTeX
@article{Roy2023,
  author = {Roy, Rubi and Ria, Tasnim and RoyMahaPatra, Debapriya and Sk, Ugir Hossain},
  title = {Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer},
  journal = {ACS Omega},
  year = {2023},
  volume = {8},
  number = {19},
  pages = {16532--16544},
  doi = {10.1021/acsomega.3c00222}
}
Kostenlos starten →